TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Revelation Biosciences ( (REVB) ) just unveiled an announcement.
Revelation Biosciences recently held its Annual Meeting where stockholders voted on several key proposals. The meeting, which took place on June 23, 2025, saw the election of a Class C director, amendments to the 2021 Equity Incentive Plan, and approval for reverse stock splits, among other decisions. Notably, the proposal to change the company’s domicile from Delaware to Nevada did not pass despite significant support. These decisions are poised to impact the company’s operational strategies and shareholder value.
The most recent analyst rating on (REVB) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.
Spark’s Take on REVB Stock
According to Spark, TipRanks’ AI Analyst, REVB is a Underperform.
Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company’s reliance on external financing due to negative cash flows adds to the risk profile.
To see Spark’s full report on REVB stock, click here.
More about Revelation Biosciences
Average Trading Volume: 1,030,146
Technical Sentiment Signal: Sell
Current Market Cap: $1.57M
See more data about REVB stock on TipRanks’ Stock Analysis page.